Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects Meeting Abstract
| Authors: | Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; Hamlin, P.; Lichtman, S. M.; Matasar, M. J.; Portlock, C. S.; Shukla, N.; Wasserheit-Lieblich, C.; Zelenetz, A. D.; Gerecitano, J. F. |
| Abstract Title: | Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349242703216 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.3487.3487 |
| Notes: | Meeting Abstract: 3487 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
